[Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
The biliary lithogenous index before and after treatment with Etofibrate, a new hypolipaemizing substance, has been assessed in dyslipidaemic subjects (ypes II and IV). Etofibrate is the result of the association of a molecule of clofibrate and one of nicotinic acid. An analysis of relative molar concentrations of biliary lipides showed that subjects with type IV and IIb dyslipidaemia produced lithogenous bile in base condition, unlike subjects with type IIa dyslipidaemia. After 28 days of treatment with Etofibrate (900 mg/die) a clear-cut increase was observed in the biliary lithogenous index in all types of dyslipidaemia examined.
D000328:Adult; D000368:Aged; D001646:Bile / Q000032:analysis / Q000187:drug effects*; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D008055:Lipids / Q000032:analysis; D008297:Male; D008875:Middle Aged
D000960:Hypolipidemic Agents; D008055:Lipids; C009746:etofibrate; D002995:Clofibric Acid; D002994:Clofibrate
Composizione lipidca biliare in soggetti dislipidemici (II e IV tipo). Effetto di un nuovo farmaco ipolipemizzante: l'Etofibrato.